BIVV001 Fusion Protein as Factor VIII Replacement Therapy for ...
2020年9月9日 · BIVV001 (rFVIIIFc-VWF-XTEN) is a novel fusion protein designed to overcome this half-life ceiling and maintain high sustained factor VIII activity levels. Data are lacking on …
BIDV
19009247 (Cá nhân) 19009248 (Doanh nghiệp) Vị trí ATM/chi nhánh
BIVV001, a new class of factor VIII replacement for hemophilia A …
2020年4月23日 · We have developed a new class of FVIII replacement, rFVIIIFc-VWF-XTEN (BIVV001), that is physically decoupled from endogenous VWF and has enhanced …
BIVV001 Fusion Protein as Factor VIII Replacement Therapy for ...
2020年9月10日 · In a small, early-phase study involving men with severe hemophilia A, a single intravenous injection of BIVV001 resulted in high sustained factor VIII activity levels, with a half …
Blood：BIVV001，一种新型FVIII替代品，用于A型血友病的止血控 …
Schratz等人开发了一种新的FVIII替代品，rFVIIIFc-VWF-XTEN (BIVV001)，在生理条件下，它可与内源性VWF解耦，并与既往所有FVIII产品相比，药代动力学特性增强。 BIVV001是一个独 …
BIVV001 (rFVIIIFc-VWF-XTEN) is a novel fusion protein designed to overcome this half-life ceiling and maintain high sustained factor VIII activity levels. Data are lacking on the safety and...
BIVV001融合蛋白作为因子Ⅷ替代品治疗A型血友病疗效显著
2020年9月14日 · BIVV001是一种新型融合蛋白，旨在克服这一半衰期上限，并维持长时间较高的因子Ⅷ活性水平。 然而，单剂量BIVV001的安全性和药代动力学尚不明确。 在这项临床1-2a …
Efanesoctocog alfa - Sanofi - AdisInsight - Springer
Efanesoctocog alfa (previously known as BIVV 001) is a fully recombinant antihemophilic factor VIII therapy being developed by Sanofi for the treatment and
Developing BIVV001, a new class of factor VIII replacement for ...
2020年2月20日 · We have developed a new class of FVIII replacement, rFVIIIFc-VWF-XTEN (BIVV001), that is physically decoupled from endogenous VWF and has enhanced …
BIVV001: The First Investigational Factor VIII Therapy to Break …
2018年11月29日 · BIVV001 (rFVIII-VWF-XTEN) is a novel investigational rFVIII therapy with single-chain FVIII, the Fc domain of human immunoglobulin G1, 2 XTEN polypeptides, and the …